Post #01: Inside the GLP-1 Boom: What a Biotech Analyst (and PhD/Nutritionist) Thinks
Manos Mastorakismanosmastorakisphd.substack.com
Post #01: Inside the GLP-1 Boom: What a Biotech Analyst (and PhD/Nutritionist) Thinks
Statins Slash GLP-1 Levels - Human Controlled Trial
(🔗 at the end)
1/9) Usually, scientific research excites me. But the paper I just read? It both excited and annoyed me.
It explores how statins – the most profitable drug in history, with annual sales exceeding $20 billion – contribute to... See more
The new obesity pills could upend American society, Derek Thompson writes.
In the early 2010s, the Danish pharmaceutical company Novo Nordisk developed a medication called semaglutide for the treatment of type 2 diabetes. It was approved by the FDA as an injectable called Ozempic. The company soon realized that... See more
instagram.com